Cesca Therapeutics Inc., the Rancho Cordova-based medical equipment firm, on Tuesday reported a loss of $4.8 million, or 12 cents per share, for its fiscal third quarter that ended March 31.
That compares with a loss of $1.9 million, or 7 cents a share, in the same period of 2014.
The year-over-year increase in net losses was related to substantial investments in development of clinical programs and increased legal and professional costs, the company said. Net quarterly revenue was $4 million, matching the year-ago total.
Cesca does research, development and commercialization of products used in regenerative medicine, including automated blood and bone marrow processing systems.
Cesca stock closed Tuesday at 92 cents a share, up 2 cents for the day.
Cesca formerly operated as ThermoGenesis Corp. It was renamed in 2014 after finalizing its merger with Los Angeles-based TotipotentRX Corp.